BG Medicine Inc., a maker of biomarker-based diagnostics in Waltham, has named Stéphane Bancel as executive chairman of the company’s board of directors. Former chairman and BG Medicine founder Noubar Afeyan will still hold a board seat.
Bancel, who has served on the BG Medicine board since January 2010, previously was CEO of bioMérieux, a French diagnostics firm. Prior to that, he was managing director of Eli Lilly in Belgium and executive director of global manufacturing strategy and supply chain at Eli Lilly in Indianapolis. Bancel earned an MBA from Harvard Business School, an M.S. degree in chemical engineering from the University of Minnesota and a master of engineering degree from École Central Paris.